Catherine Skari

FT-4202 Granted FDA Fast Track, Rare Pediatric Disease Designations for SCD

FT-4202, a potential disease-modifying oral treatment for sickle cell disease being developed by Forma Therapeutics, has been given fast track and rare pediatric disease designations by the…

Read More »

Rare Disease Day 2020: Abundance of events & vast participation are expected in this year’s RDD

  Observed every year on the last day of February and in the 29th of February in 2020, Rare Disease…

Read More »

FAiTh Society Pakistan organised a series of special events for patients with thalassaemia

Read More »

Applications now open for TIF’s Renzo Galanello Fellowship Programme 2020

TIF‘s Renzo Galanello Fellowship Programme is back again in 2020!   A small number of physicians, specialists in the field…

Read More »

A UNITED Onlus Delegation From Italy Visits TIF – 7 February 2020

In recent years the Federation has engaged in order to strengthen the dissemination and penetration of its resources and educational…

Read More »

‘FAiTh – Fight Against Thalassemia Association’ presents its activities for January 2020

  The ‘FAiTh – Fight Against Thalassemia’ group,  a longtime member of TIF operating in Pakistan, is dedicated to support,…

Read More »

FDA grants Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease & β-thalassaemia

  An investigational gene therapy for Sickle Cell Disease (SCD) and β-thalassaemia, known as ARU-1801, has been given Orphan Drug Designation an…

Read More »

Chiesi Group and Apotex Inc. finalize agreement for the acquisition of Ferriprox® (Deferiprone)

  Chiesi Farmaceutici and Apotex (together with its American subsidiary, ApoPharma Usa), a company engaged in haematology and in the…

Read More »

TIF’s latest Newletter is out now!

Catch up with our most recent newsletter and get informed about TIF’S activities and achievements in the past few months!…

Read More »

Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany

  Bluebird bio, Inc. announced earlier today the launch  of ZYNTEGLO™ in Germany,  the company’s one-time gene therapy for patients…

Read More »